Target intelligence / Profile preview

SET binding factor 1 (SBF1)

Target
SBF1
Molecular classification
Other (Myotubularin protein family, catalytically inactive phosphatase), Adapter protein, Guanine nucleotide exchange factor (GEF) domain containing protein
01

Overview

SET binding factor 1 (SBF1) is a large, multidomain protein encoded by the SBF1 gene located on chromosome 22q13.33, and is also known as myotubularin-related protein 5 (MTMR5)[1][2][4]. SBF1 is a member of the myotubularin family, characterized as a catalytically inactive protein tyrosine phosphatase due to missing key residues in its active site[1][6]. It has a guanine nucleotide exchange factor (GEF) domain, enabling it to activate small Rab GTPases, notably RAB28, which are involved in endolysosomal trafficking[1]. SBF1 acts as an adapter protein for the active phosphatase MTMR2, regulating its localization and function—key for processes such as autophagy and Schwann cell myelination[1]. SBF1 is predominantly expressed in the brain and skeletal muscle; its dysregulation or mutation is associated with disorders such as Charcot-Marie-Tooth disease type 4B3 (CMT4B3) and possibly late-onset neurocognitive disorders including Alzheimer’s disease[1][2][4]. SBF1 is not an established therapeutic target for any approved drugs and has no known drug interactions[1][3].

Other names
Myotubularin-related protein 5MTMR5DENND7AInactive phosphatidylinositol 3-phosphatase 5DENN/MADD domain containing 7ACMT4B3
02

Biological functions

Adapter for phosphatase MTMR2, regulating MTMR2 activity and localizationGuanine nucleotide exchange factor activity (activating Rab proteins, e.g., RAB28)Suppression of neuronal autophagyRegulation of endosomal traffickingPositive regulation of Schwann cell myelination (late-stage radial sorting)Inhibition of myoblast differentiationPromotion of oncogenic transformation in fibroblasts[1][3]
03

Disease associations

Charcot-Marie-Tooth disease, Demyelinating, type 4B3 (CMT4B3)[1][4]Charcot-Marie-Tooth disease type 4B3Neurocognitive disorders (potentially Alzheimer’s disease; based on epigenetic/STR studies)[2]
04

Safety considerations

No specific safety or toxicity concerns documented as direct consequences of targeting SBF1, as it is not known as a therapeutic drug target
05

Biomarkers

SBF1 (GCC)-repeat variant in 5' UTR associated with neurocognitive disorders and altered allele frequency in Charcot-Marie-Tooth disease[2]No established clinical biomarkers in practice

Beyond the preview

Go deeper on SET binding factor 1 (SBF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SET binding factor 1 (SBF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call